FY2025 EPS Estimate for Kura Oncology Raised by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Brookline Capital Management boosted their FY2025 earnings per share (EPS) estimates for Kura Oncology in a research report issued to clients and investors on Thursday, November 21st. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($1.74) for the year, up from their previous forecast of ($2.27). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

Several other analysts have also recently commented on the company. HC Wainwright raised their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday. Finally, Bank of America cut their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Trading Up 7.4 %

Kura Oncology stock opened at $10.80 on Monday. Kura Oncology has a 52-week low of $9.06 and a 52-week high of $24.17. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86. The firm has a 50-day moving average price of $17.88 and a two-hundred day moving average price of $19.67.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC grew its stake in Kura Oncology by 8.2% in the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares during the period. Sofinnova Investments Inc. increased its position in Kura Oncology by 64.4% during the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the period. Armistice Capital LLC boosted its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares during the period. Finally, Alethea Capital Management LLC grew its position in Kura Oncology by 108.2% in the 3rd quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock worth $10,816,000 after purchasing an additional 287,636 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.